|
Vitamin D, alcohol, and risk of lymphomas in a prospective cohort of women
|
5R03CA135687-02
|
$72,500
|
$21,750
|
Chang, Ellen
|
CANCER PREVENTION INSTIT OF CALIFORNIA
|
|
Virus Hunting
|
ZIA CP005782 10058
|
$12,198
|
$3,050
|
Goedert, James
|
DCEG (NCI)
|
|
Veterans Administration hospitalization database, Patient Treatment File, and Out
|
ZIA CP010126 00580
|
$85,856
|
$4,293
|
McGlynn, Katherine
|
DCEG (NCI)
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-37S1
|
$101,020
|
$1,010
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-37S2
|
$148,912
|
$1,489
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-37
|
$4,795,480
|
$47,955
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UT M.D. Anderson Cancer Center Lymphoma SPORE
|
5P50CA136411-02
|
$500,000
|
$115,000
|
YOUNES, ANAS
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Understanding T Cell Rapamycin Resistance
|
ZIA BC 011220
|
$272,277
|
$27,228
|
Fowler, Daniel
|
CCR (NCI)
|
|
Tumor-Infiltrating Donor Derived Lymphocyte Therapy After Allogeneic Transplant
|
ZIC BC 011029
|
$159,656
|
$63,862
|
Hakim, Frances
|
CCR (NCI)
|
|
Transplant cancer match
|
ZIA CP010176 10291
|
$51,619
|
$5,162
|
Engels, Eric
|
DCEG (NCI)
|
|
Towards a Mouse Model of Classical Hodgkin's Disease and PTLD
|
5R01CA098285-07
|
$494,023
|
$494,023
|
RAJEWSKY, KLAUS
|
IMMUNE DISEASE INSTITUTE, INC.
|
|
The Role of Fbxw7 in genetic instability and cancer
|
5R01CA116481-04
|
$355,982
|
$71,196
|
Mao, Jian-Hua
|
UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-17S1
|
$75,066
|
$1,501
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-17S2
|
$100,000
|
$2,000
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
5P30CA060553-17
|
$5,047,305
|
$100,946
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S4
|
$3,823,791
|
$38,238
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S5
|
$100,000
|
$1,000
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S6
|
$50,000
|
$500
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S7
|
$80,000
|
$800
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S8
|
$200,000
|
$2,000
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Mechanism of Thymic Lymphomagenesis in Genetically Engineered Mouse Model
|
ZIA BC 011192
|
$222,556
|
$111,278
|
Van Dyke, Terry
|
CCR (NCI)
|
|
Symptom Cluster Subgroups in Adult Survivors of Childhood Cancers
|
5R01CA136912-02
|
$239,033
|
$23,903
|
Finnegan, Lorna
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
Sweden and Denmark linked registries on hospital discharges and subsequent cancer
|
ZIA CP010183 00560
|
$113,406
|
$5,670
|
Anderson, William
|
DCEG (NCI)
|
|
Support for Human Specimen Banking in NCI-Supported Cancer Clinical Trials
|
3U24CA114766-05S1
|
$1,195,618
|
$119,562
|
Ramirez, Nilsa
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Study of the Roles of SDF1 and CXCR4 in Hematopoiesis
|
ZIA BC 010782
|
$344,821
|
$86,205
|
Tosato, Giovanna
|
CCR (NCI)
|
|
Study of Structures of CCR5 and Its Interactions with CCR5 Inhibitors
|
ZIA BC 011109
|
$299,176
|
$59,835
|
Mitsuya, Hiroaki
|
CCR (NCI)
|
|
Study of HIV Protease Dimerization (PD) and Identification of PD Inhibitors
|
ZIA BC 011105
|
$149,588
|
$1,496
|
Mitsuya, Hiroaki
|
CCR (NCI)
|
|
Studies of Epstein-Barr Virus
|
5R37CA012055-38
|
$461,604
|
$115,401
|
MILLER, I.
|
YALE UNIVERSITY
|
|
Statins & Lymphoid Malignancy Risk in a Large Multi-Site Population-Based Cohort
|
1R01CA140754-01A1
|
$692,432
|
$346,216
|
Johnson, Christine C
|
HENRY FORD HEALTH SYSTEM
|
|
SPORE in Lymphoma
|
3P50CA126752-04S1
|
$340,000
|
$95,200
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
5P50CA126752-04
|
$2,266,618
|
$634,653
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
Signal Transduction Pathways in CD30-positive Lymphomas
|
1R01CA142809-01A1
|
$137,479
|
$68,740
|
DUCKETT, COLIN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Signal transduction inhibitor therapy for Lymphoma
|
5R01CA127433-04
|
$339,520
|
$169,760
|
Witzig, Thomas
|
MAYO CLINIC
|
|
Research Management and Support
|
RMS2010 [E]
|
$345,370,533
|
$26,989
|
N/A
|
National Cancer Institute
|
|
Relapse after Allogeneci Hematopoietic Stem Cell Transplantation
|
ZIA BC 011239
|
$183,397
|
$36,679
|
Bishop, Michael
|
CCR (NCI)
|
|
Regulation of RANTES expression in T lymphocytes
|
ZIA BC 011025
|
$640,564
|
$128,113
|
Krensky, Alan
|
CCR (NCI)
|
|
Regulation of Exocytosis from Immune Cells
|
ZIA BC 011035
|
$299,248
|
$74,812
|
Roche, Paul
|
CCR (NCI)
|
|
Regulation of Epstein-Barr Virus Latency
|
5R01CA093606-08
|
$303,280
|
$242,624
|
LIEBERMAN, PAUL
|
WISTAR INSTITUTE
|
|
Registry linkage projects [including Scandinavia, SEER Medicare, other]
|
ZIA CP010150 10359
|
$356,997
|
$71,399
|
Engels, Eric
|
DCEG (NCI)
|
|
Regional Oncology Research Center
|
3P30CA006973-48S1
|
$100,000
|
$2,000
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-48S2
|
$47,307
|
$946
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
5P30CA006973-48
|
$7,708,192
|
$154,164
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Receptor-directed Therapy
|
ZIA BC 010603
|
$678,125
|
$203,437
|
Janik, John
|
CCR (NCI)
|
|
Radiation dose- response and second primary cancers of stomach, esophagus, and pa
|
ZIA CP010131 04134
|
$377,173
|
$56,576
|
Morton, Lindsay
|
DCEG (NCI)
|
|
Predictors of Optimal Immune Reconstitution in Stem Cell Transplant Patients
|
1R21CA133343-01A2
|
$193,793
|
$65,890
|
Costanzo, Erin
|
UNIVERSITY OF WISCONSIN MADISON
|
|
Prediction of Second Cancer Risks for Children Treated with Proton - vs. - Photon
|
5R01CA131463-03
|
$255,640
|
$89,474
|
Newhauser, Wayne
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Post-Transcriptional Regulation of Interleukin-7 Receptor Expression
|
ZIA BC 011214
|
$441,409
|
$44,141
|
Park, Jung-Hyun
|
CCR (NCI)
|
|
Phase I Trials of Anti-Cancer Agents
|
7U01CA076576-13
|
$762,134
|
$129,563
|
GREVER, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Phase I and II Study of BCL Family Inhibitors in Lymphoma
|
ZIA BC 010716
|
$177,617
|
$53,285
|
Wilson, Wyndham
|
CCR (NCI)
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 010764
|
$2,442,501
|
$122,125
|
Wayne, Alan
|
CCR (NCI)
|
Total relevant funding to Hodgkins disease for this search: $14,614,781
|